Almost every drug approved over the past two decades has changed stewardship during the course of its development.
Curadev works in the early stages of the drug discovery and development phase and has always welcomed interest from organizations with strengths and expertise that can bring out the value of our portfolio. We have been successful in establishing alliances with some of the world’s most innovative biotechs and prestigious pharmaceutical firms.
Curadev and Karyopharm, USA sign a drug discovery collaboration agreement under which Curadev will select a target for co-development until Phase 1 clinical trials before handing the drug candidate over to Karyopharm for further development.
Curadev and Bayer, Germany, sign a research collaboration and license agreement to develop novel STING antagonists
Curadev receives first milestone payment from the out-licensing of its novel small molecule STING agonist to Takeda Pharmaceuticals
Curadev announces research collaboration and licensing agreement to develop cancer immunotherapeutic with Roche
Curadev partners its dual kinase inhibitor program with Medivation, Inc, USA
Curadev receives first milestone payment in its immune oncology small molecule collaboration with Endo Pharma
Curadev signs extensive research collaboration deal with Medivation, Inc, USA
Curadev announces research collaboration and licensing agreement to develop cancer immunotherapeutic with Endo Pharma